CHAMPIONS ONCOLOGY, INC.

Champions Oncology, Inc. filed its Form 10-Q for the quarterly period ended July 31, 2026. The company reported a net loss of $426,000, an improvement from the $466,000 net loss in the same period last year. Oncology revenue saw an increase to $15.23 million from $13.99 million year-over-year. Total assets and liabilities both increased significantly from the previous quarter. The company also reported a substantial rise in stock-based compensation expense.

Champions Oncology, Inc. reported fiscal year 2026 revenue of approximately $59.4 million, a 4% increase year-over-year, alongside a net loss of $1.2 million and an accumulated deficit of $81.1 million. The company utilized $4.5 million in cash from operations and held a cash balance of $4.9 million. Champions Oncology is a technology-enabled research organization focused on oncology drug discovery and development, leveraging its proprietary PDX models and Datacenter across research services, SaaS, and drug discovery business lines. The company increased its R&D spending to $9.1 million and believes it has sufficient capital to fund operations through at least August 2027.

Champions Oncology, Inc. announced record annual revenue of $59.4 million for its fiscal year ended April 30, 2026, alongside fourth-quarter revenue of $13.8 million, a 12% increase year-over-year. The company reported positive Adjusted EBITDA for all four quarters of fiscal year 2026, totaling $1.6 million for the full year and $158,000 for the fourth quarter. Management highlighted continued strategic investments in radiopharmaceuticals, its data platform, and commercial expansion to support future growth.